3,413 件 ・ 関連度順
概要と使いどころ
Breadboard circuit mockups via HTML5 Canvas. Use when creating circuit layouts, visualizing 6502/retro electronics components, drawing breadboard diagrams, or designing vintage computer schematics with discrete parts.
日本語の概要は準備中です。原文の説明を表示しています。
Orchestrates the tdmcp feature team end-to-end: design/wireframe → build → integrate → QA → release. Use whenever the user wants to build, implement, develop, ship, or add one or more tdmcp features/tools/effects/controls/AI-prompts for TouchDesigner, or to run them through a coordinated design→develop→QA→deploy pipeline. Also use for follow-ups: re-run, continue, update, fix, or improve a feature/batch, ship the next version, or rebuild just one part of a previous run. Single feature or a whole batch.
日本語の概要は準備中です。原文の説明を表示しています。
iOS design system tokens for Pencil MCP: SF Pro typography scale, iOS semantic colors (light + dark mode hex values), spacing grid, touch targets, corner radii, and component heights. Use when initializing a .pen file for iOS design or setting up design variables.
日本語の概要は準備中です。原文の説明を表示しています。
Set up and configure WorkOS AuthKit authentication with Convex backend. Use when integrating AuthKit, configuring JWT providers, setting up environment variables, or implementing sign in and sign out flows with React and Vite. Supports Netlify deployment.
日本語の概要は準備中です。原文の説明を表示しています。
Securing container registry images by implementing vulnerability scanning with Trivy and Grype, enforcing image signing with Cosign and Sigstore, configuring registry access controls, and building CI/CD pipelines that prevent Dağıt:ing unscanned or unsigned images.
日本語の概要は準備中です。原文の説明を表示しています。
End-to-end ABM program design and orchestration for B2B SaaS mid-market and enterprise motions. Use when building a target account list, designing account tiering criteria, planning ABM channel orchestration, coordinating BDR outreach with marketing campaigns, defining ABM measurement frameworks, or running an ABM program review. Also use when asked to "build an ABM program," "set up account-based marketing," "design a target account strategy," "plan ABM campaigns," or "measure ABM results." Designed for demand gen teams selling to Mid-Market companies with $10K-$50K+ ACV, multi-persona buying committees, and 3-6 month sales cycles.
日本語の概要は準備中です。原文の説明を表示しています。
Focused Signals scout for PostHog setup health. Reads the project's active health issues — the deterministic findings of PostHog's own health checks (no live events, outdated SDKs, missing reverse proxy, absent web vitals, ingestion warnings, failing data-warehouse models, and more) — and decides which are genuinely worth surfacing. Unlike a one-signal-per-issue push, it bundles kind-clusters into a single finding, weights by real blast radius (cross-referencing actual event volume and reach), and prioritizes issues an agent can resolve via the MCP. Emits only above the confidence bar; otherwise writes durable memory and closes out empty. Self-contained peer in the signals-scout-* fleet — no dependencies on other skills.
日本語の概要は準備中です。原文の説明を表示しています。
Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.
日本語の概要は準備中です。原文の説明を表示しています。
Designs novel molecules using REINVENT 4 (de novo, scaffold decoration, linker design, R-group, molecular optimization), MolMIM, Diffusion-based generators (DiGress, DiffSMol), and JT-VAE with explicit handling of multi-parameter optimization (MPO), goal-directed scoring functions, transfer/reinforcement/curriculum learning, synthetic accessibility scoring, and chemical space exploration vs exploitation. Use when designing new chemical matter against a target, decorating a scaffold, linking fragments, or optimizing a hit for multiple ADMET / activity properties simultaneously.
日本語の概要は準備中です。原文の説明を表示しています。
Analyze, plan, and execute Adobe SDK upgrades — including the critical JWT-to-OAuth migration, PDF Services SDK v3-to-v4, and Photoshop API endpoint changes (cutout v1 to remove-background v2). Trigger with phrases like "upgrade adobe", "adobe migration", "adobe breaking changes", "update adobe SDK", "jwt to oauth".
日本語の概要は準備中です。原文の説明を表示しています。
Detects m6A modifications from Oxford Nanopore direct-RNA-sequencing (ONT DRS) signal data using m6Anet (Hendra 2022 *Nat Methods* 19:1590; multiple-instance-learning neural network over DRACH 5-mer signal). Covers the required upstream pipeline (Dorado / Guppy basecalling -> minimap2 transcriptome alignment with `-ax map-ont -uf -k14 --secondary=no` -> nanopolish eventalign with `--scale-events --signal-index` (m6Anet-required) plus `--summary` / `--threads` housekeeping -> m6anet dataprep -> m6anet inference), per-site vs per-read probability interpretation including the `mod_ratio` per-site stoichiometry column, the DRACH-only modeling constraint, minimum-coverage thresholds (20-50 reads per site for stable probability estimates), multi-condition comparison via xPore (Pratanwanich 2021 *Nat Biotechnol* 39:1394), Nanocompore (Leger 2021 *Nat Commun* 12:7198), ELIGOS (Jenjaroenpun 2021 *NAR* 49:e7), and Dorado native modification calling (RNA004 chemistry, 2024+), reference-transcriptome version pinning, the cDNA-vs-DRS chemistry distinction (cDNA-Nanopore CANNOT be used for modification detection), and orthogonal validation against MeRIP / GLORI. Use when calling m6A from ONT DRS without immunoprecipitation, choosing m6Anet vs xPore vs Nanocompore vs ELIGOS vs Dorado native, interpreting per-site `probability_modified` vs `mod_ratio` vs per-read modification probabilities, comparing methylation between conditions from ONT data, deciding between m6Anet for known DRACH sites and Dorado/Remora for genome-wide screening, pinning RNA002 vs RNA004 chemistry and basecaller model versions, or troubleshooting eventalign / dataprep failures.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes CRISPR drug-modifier (chemogenomic) screens with drugZ (Li & Hart 2019 Genome Med), a bidirectional Z-score method that identifies synthetic-lethal sensitizing genes and resistance-conferring suppressor genes from vehicle vs drug comparisons. Covers vehicle-anchored design (not Day-0), the bidirectional Z math giving 2-3x sensitivity over MAGeCK / STARS / edgeR / RIGER on drug screens, per-gene sumZ and normZ, synth (sensitizer) vs supp (suppressor) FDR, multi-dose handling, integration with control sgRNAs, and comparison with MAGeCK MLE with dose covariate. Use when running a drug-modifier CRISPR screen, identifying sensitizing or resistance genes for a drug candidate, choosing drugZ vs MAGeCK MLE for chemogenomic analysis, troubleshooting low-effect drug screens where MAGeCK lacks sensitivity, or designing a drug-screen layout (vehicle vs drug arms).
日本語の概要は準備中です。原文の説明を表示しています。
Designs novel molecules using REINVENT 4 (de novo, scaffold decoration, linker design, R-group, molecular optimization), MolMIM, Diffusion-based generators (DiGress, DiffSMol), and JT-VAE with explicit handling of multi-parameter optimization (MPO), goal-directed scoring functions, transfer/reinforcement/curriculum learning, synthetic accessibility scoring, and chemical space exploration vs exploitation. Use when designing new chemical matter against a target, decorating a scaffold, linking fragments, or optimizing a hit for multiple ADMET / activity properties simultaneously.
日本語の概要は準備中です。原文の説明を表示しています。
Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.
日本語の概要は準備中です。原文の説明を表示しています。
Improve code structure, readability, and maintainability without changing external behavior through systematic refactoring techniques like extracting functions, removing duplication, simplifying conditionals, and applying design patterns. Use when reducing technical debt, extracting functions or classes, removing code duplication, simplifying complex conditionals, renaming for clarity, applying design patterns, improving code organization, reducing coupling, increasing cohesion, or maintaining test coverage during structural improvements.
日本語の概要は準備中です。原文の説明を表示しています。
Render a proposed redesign of a page on the current website as a self-contained static HTML file, then iterate via the impeccable craft loop. Per-page, idempotent, stale-aware. Use when the user asks for a redesign prototype, a before/after comparison, a design preview, a page mockup, a visual diff of the redesign, or invokes /stardust:prototype.
日本語の概要は準備中です。原文の説明を表示しています。
Creates complete AEM components with dialog, HTL template, Sling Model, unit tests, and clientlibs. Supports extending Core Components and project components. When a Figma design URL is provided, fetches the design via Figma MCP (get_design_context) and translates it into pixel-perfect HTL, CSS, and JS. Follows Adobe Experience League best practices for AEM Cloud Service and 6.5. Use this skill whenever the user mentions creating, building, generating, or scaffolding an AEM component, or mentions component types like teaser, card, hero, banner, accordion, tabs, carousel, list, navigation, breadcrumb, or any custom AEM component. Also trigger when the user wants to extend a Core Component, create a component dialog, add a Sling Model, or convert a Figma design into an AEM component.
日本語の概要は準備中です。原文の説明を表示しています。
Validate process decomposition and architecture design quality before execution begins. Load when the setup-evaluator agent fires (automatic for agent-chain tasks), or when user says "evaluate this setup", "check the decomposition", "validate the architecture", "is this plan sound", "review the agent design". Catches structural errors, missing knowledge, unrealistic step ordering, and topology mismatches. Does NOT modify — only evaluates.
日本語の概要は準備中です。原文の説明を表示しています。
Detects m6A modifications from Oxford Nanopore direct-RNA-sequencing (ONT DRS) signal data using m6Anet (Hendra 2022 *Nat Methods* 19:1590; multiple-instance-learning neural network over DRACH 5-mer signal). Covers the required upstream pipeline (Dorado / Guppy basecalling -> minimap2 transcriptome alignment with `-ax map-ont -uf -k14 --secondary=no` -> nanopolish eventalign with `--scale-events --signal-index` (m6Anet-required) plus `--summary` / `--threads` housekeeping -> m6anet dataprep -> m6anet inference), per-site vs per-read probability interpretation including the `mod_ratio` per-site stoichiometry column, the DRACH-only modeling constraint, minimum-coverage thresholds (20-50 reads per site for stable probability estimates), multi-condition comparison via xPore (Pratanwanich 2021 *Nat Biotechnol* 39:1394), Nanocompore (Leger 2021 *Nat Commun* 12:7198), ELIGOS (Jenjaroenpun 2021 *NAR* 49:e7), and Dorado native modification calling (RNA004 chemistry, 2024+), reference-transcriptome version pinning, the cDNA-vs-DRS chemistry distinction (cDNA-Nanopore CANNOT be used for modification detection), and orthogonal validation against MeRIP / GLORI. Use when calling m6A from ONT DRS without immunoprecipitation, choosing m6Anet vs xPore vs Nanocompore vs ELIGOS vs Dorado native, interpreting per-site `probability_modified` vs `mod_ratio` vs per-read modification probabilities, comparing methylation between conditions from ONT data, deciding between m6Anet for known DRACH sites and Dorado/Remora for genome-wide screening, pinning RNA002 vs RNA004 chemistry and basecaller model versions, or troubleshooting eventalign / dataprep failures.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes CRISPR drug-modifier (chemogenomic) screens with drugZ (Li & Hart 2019 Genome Med), a bidirectional Z-score method that identifies synthetic-lethal sensitizing genes and resistance-conferring suppressor genes from vehicle vs drug comparisons. Covers vehicle-anchored design (not Day-0), the bidirectional Z math giving 2-3x sensitivity over MAGeCK / STARS / edgeR / RIGER on drug screens, per-gene sumZ and normZ, synth (sensitizer) vs supp (suppressor) FDR, multi-dose handling, integration with control sgRNAs, and comparison with MAGeCK MLE with dose covariate. Use when running a drug-modifier CRISPR screen, identifying sensitizing or resistance genes for a drug candidate, choosing drugZ vs MAGeCK MLE for chemogenomic analysis, troubleshooting low-effect drug screens where MAGeCK lacks sensitivity, or designing a drug-screen layout (vehicle vs drug arms).
日本語の概要は準備中です。原文の説明を表示しています。
Designs novel molecules using REINVENT 4 (de novo, scaffold decoration, linker design, R-group, molecular optimization), MolMIM, Diffusion-based generators (DiGress, DiffSMol), and JT-VAE with explicit handling of multi-parameter optimization (MPO), goal-directed scoring functions, transfer/reinforcement/curriculum learning, synthetic accessibility scoring, and chemical space exploration vs exploitation. Use when designing new chemical matter against a target, decorating a scaffold, linking fragments, or optimizing a hit for multiple ADMET / activity properties simultaneously.
日本語の概要は準備中です。原文の説明を表示しています。
Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.
日本語の概要は準備中です。原文の説明を表示しています。
Build low-fidelity wireframes, screen mockups, and user-flow diagrams in Frame0 (the hand-drawn Balsamiq-style wireframing tool) through its connected MCP server. Use when asked to wireframe a screen, sketch a UI, make a low-fi mockup, lay out an app's screens, or diagram a user flow with clickable links. Triggers: "wireframe", "frame0", "low-fi mockup", "sketch a screen", "user flow", "lo-fi", "rough out the UI". NOT for high-fidelity visual design, brand systems, or color/typography polish (use web-design-expert / Figma); NOT for production UI code (use frontend skills).
日本語の概要は準備中です。原文の説明を表示しています。
Generate, fill, and assemble PDF documents at scale. Handles legal forms, contracts, invoices, certificates. Supports form filling (pdf-lib), template rendering (Puppeteer, LaTeX), digital signatures (DocuSign), and document assembly. Use for legal tech, HR automation, invoice generation. Activate on "PDF generation", "form filling", "document automation", "digital signatures". NOT for simple PDF viewing, basic file conversion, or OCR text extraction.
日本語の概要は準備中です。原文の説明を表示しています。